Selecta inks discovery deal with Sanofi worth up to $900M

Vaccine outfit Selecta Biosciences has signed an agreement with Sanofi ($SNY) to discover antigen-specific immunotherapies for food allergies, and the deal includes rights to an initial therapy with the option to develop two more. Selecta is due up to $900 million in milestones, plus a cut of sales. Report

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.